According to the CSCO guidelines, oligoprogression or only progression in central nervous system (CNS) of NSCLC with EGFR mutation in stage IV after drug resistance, the original EGFR-TKI and local treatment can be continued, and the mechanism of drug resistance can be confirmed by biopsy again. This evidence concerns the gene EGFR and non-small cell lung carcinoma.